CoronaryAtlas logo
CoronaryAtlas
Very-Low-Density Lipoprotein
Pathway / Lipid retention & oxidation

Very-Low-Density Lipoprotein

lipoprotein

VLDL, an apoB-containing atherogenic lipoprotein, accumulates in the arterial intima where it undergoes oxidative modification, initiating atherosclerotic plaque formation.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleApoB-containing atherogenic particle; retained in arterial intima and subject to oxidative modification.
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresIndeterminate
R — rupture / Type-I
67
C — confounder / Type-II
—
A — assay feasibility
82
E — evidence strength
46
T1DI (composite)
22
Specificity differential (R−C)+17
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmian/a
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 0/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 2 supporting references. See the discrimination table for all markers.

Assay & specimen

Specialized reference method
Specimen
Serum or plasma (EDTA)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
NMR lipoprotein particle analysis or density-gradient ultracentrifugation
Reagent / substrate
No chemical reagent — NMR spectral deconvolution of lipid methyl signals (or ultracentrifugal separation by density)
Platform
NMR (LabCorp NMR LipoProfile) / analytical ultracentrifuge
Turnaround · availability
Send-out · Specialized reference lab

Literature evidence(21)